Attorney Docket No.: VPI/02-110 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

10/609,147

Confirmation No.:

6705

Filing Date:

June 27, 2003

Examiner:

Paul V. Ward

Group Art Unit:

1624

Applicants:

Knegtel et al.

For:

CASPASE INHIBITORS AND USES THEREOF

Certificate of Mailing Under 37 CFR §1.8

I hereby certify that this correspondence and any documents referred to as attached hereto are being deposited with the U.S. Postal Service with sufficient postage as Express Mail Label No. EV804431422US in an envelope addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on February 27, 2007.

ou itt i oneiuno

February 27, 2007 Cambridge, Massachusetts

Mail Stop: RCE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Transmitted herewith is a Request for Continued Examination (RCE) Transmittal, a Supplemental Information Disclosure Statement, a Form 1449/PTO with copies of references B1-B5 and C1-C7 to be filed in the above-identified patent application.

	icant: Knegtel et al.							
Application No.: 10/609,147								
FEE	FOR ADDITIONAL C		required					
	A fee for additional claims is not required.							
[]	A fee for additional claims is required.							
	The additional fee ha	as been calcu	lated as show	vn below:				
	CLAIMS REMAINING AFTER AMENDMENT	HIGHES NUMBE PREVIO PAID FO	R PI USLY E	RESENT XTRA	RATE		ADDITIO FEES	NAL
TOT	AL CLAIMS	•	* =	Х	\$ 50	=	\$	0
INDE CLA	EPENDENT IMS	_	** =	Х	\$200	=	\$	0
	T PRESENTATION O TIPLE DEPENDENT			+	\$360	=	\$	
*	If less than 20, insert 3		To	OTAL			\$	0
[]	A check in the amou	nt of \$ in	payment of t	he filing fe	e is trans	mitted	d herewitl	n.
[]	Please charge \$to	•		•	•	f the	filing fee.	Α

- duplicate copy of this transmittal letter is transmitted herewith.
- [X] The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

EXTENSION FEE

The following extension is applicable to the Response filed herewith; [] \$120.00 extension fee for response within first month pursuant to 37 C.F.R. § 1.136(a); [] \$450.00 extension fee for response within second month pursuant to 37 C.F.R. § 1.136(a); [] \$1,020.00 extension fee for response within third month pursuant to 37 C.F.R. § 1.136(a); [] \$1,590.00 extension fee for response within fourth month

Applicant: Knegtel et al.	
Application No.: 10/609,147	

pursuant to 37 C.F.R. § 1.136(a); [] \$2,160.00 within fifth month pursuant to 37 C.F.R. § 1.136(a).

- [] A check in the amount of [] \$120.00; [] \$450.00; [] \$1,020.00; [] \$1,590.00; [] \$2,160.00 in payment of the extension fee is transmitted herewith.
- [] Please charge the extension fee in the amount of [] \$120.00; [] \$450.00; [] \$1,020.00; [] \$1,590.00; [] \$2,160.00 to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.
- [X] The Director is hereby authorized to charge payment of any additional fees required under 37 C.F.R. § 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

MISCELLANEOUS FEES

[X] Please charge \$790.00 to Deposit Account No. 50-0725 in payment of the RCE (Request for Continued Examination) and filing fee. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,

Susan C. Kelly, Reg. No. 58,046

Agent for Applicants

Lisa A. Dixon, Reg. No. 40,995

Attorney for Applicants

c/o Vertex Pharmaceuticals Incorporated

130 Waverly Street

Cambridge, MA 02139-4242

Tel.: (617) 444-7374 Fax.: (617) 444-6483 Customer No. 27916

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

10/609,147

Confirmation No.:

6705

Filing Date:

June 27, 2003

Examiner:

Paul V. Ward

Group Art Unit:

1624

Applicants:

Knegtel et al.

For:

CASPASE INHIBITORS AND USES THEREOF

FEB 2 7 2007

February 27, 2007 Cambridge, Massachusetts

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

(a)		1449/PTO be considered and made of record in the above-identified patent application.			
	\boxtimes	Copies of references Citation Nos. <u>B1-B5; C1-C7</u> are attached.			
		Copy(ies) of references Citation No(s) was/were filed in application U.S. Application No(s) filed, from which this application claims priority under 35 U.S.C. § 120.			
		A copy of the International Search Report received in the corresponding PCT Application No is attached herewith.			
(b)	\boxtimes	No fee is believed due because:			
		The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.			
		The Information Disclosure Statement is being concurrently filed with the above-identified application.			
		The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).			
		The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.			
(c)		The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and			
		Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart			

*Applicants: Ronald Knegtel Application No.: 10/609,147

 \boxtimes

		foreign application not more than three months prior to the filing of this Information Disclosure Statement; or			
		No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or			
		The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.			
(d)	The In issue for	formation Disclosure Statement is being filed on or before the payment of the ee; and			
		Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or			
		No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and			
		The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.			
The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.					

Respectfully submitted,

Susan C. Kelly, Reg. No. 58,046

Agent for Applicants

Lisa A. Dixon, Reg. No. 40,995

Attorney for Applicants

c/o Vertex Pharmaceuticals Incorporated

130 Waverly Street

Cambridge, MA 02139-4242

Tel.: (617) 444-7374 Fax.: (617) 444-6483

Customer No. 27916